Activation of Human Prothrombin by Arginine-specific Cysteine Proteinases (Gingipains R) from Porphyromonas gingivalis*

Takahisa ImamuraDagger , Agnieszka Banbula§, Pedro J. B. Pereira||, James Travis**, and Jan Potempa§**DaggerDagger

From the Dagger  Division of Molecular Pathology, Department of Neuroscience and Immunology, Kumamoto University Graduate School of Medical Sciences, Kumamoto 860, Japan, the § Department of Microbiology, Institute of Molecular Biology, Jagiellonian University, 31-120 Kraków, Poland,  Abteilung Strukturforschung, Max-Planck-Institut für Biochemie, Martinsried, D-82152 Germany, and the ** Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia 30602

Received for publication, July 27, 2000, and in revised form, March 13, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The effect of 95- (HRgpA) and 50-kDa gingipain R (RgpB), arginine-specific cysteine proteinases from periodontopathogenic bacterium Porphyromonas gingivalis on human prothrombin activation was investigated. Each enzyme released thrombin from prothrombin in a dose- and time-dependent manner with the former enzyme, containing adhesion domains, being 17-fold more efficient than the single chain RgpB. A close correlation between the generation of fibrinogen clotting activity and amidolytic activity indicated that alpha -thrombin was produced by gingipains R, and this was confirmed by SDS-polyacrylamide gel electrophoresis, thrombin active site labeling, and amino-terminal sequence analysis of prothrombin digestion fragments. Significantly, the catalytic efficiency of HRgpA to generate thrombin (kcat/Km = 1.2 × 106 M-1 s-1) was 100-fold higher than that of RgpB (kcat/Km = 1.2 × 104 M-1 s-1). The superior prothrombinase activity of HRgpA over RgpB correlates with the fact that only the former enzyme was able to clot plasma, and kinetic data indicate that prothrombin activation can occur in vivo. At P. gingivalis-infected periodontitis sites HRgpA may be involved in the direct production of thrombin and, therefore, in the generation of prostaglandins and interleukin-1, both have been found to be associated with the development and progression of the disease. Furthermore, by taking into account that the P. gingivalis bacterium has been immunolocalized in carotid atherosclerotic plaques at thrombus formation sites (Chiu, B. (1999) Am. Heart J. 138, S534-S536), our results indicate that bacterial proteinases may potentially participate in the pathogenesis of cardiovascular disease associated with periodontitis.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Blood coagulation is an important defense system, protecting the body against blood loss from injured vessels. The process is initiated by the binding of factor VII to tissue factor (1), present in tissues surrounding vessels (2), followed by proteolytic activation of plasma coagulation factors in a cascade pathway (3-5). Thrombin, the ultimate product of these reactions, is an extremely potent platelet activator (6, 7) and converts fibrinogen to a fibrin clot (8), thus plugging damaged vessels. Besides its central role in hemostasis, thrombin also enhances vascular permeability (9), induces leukocyte chemotaxis (10, 11), and potentiates lipopolysaccharide-stimulated interleukin-1 production by macrophages (12). These data, and the fact that prothrombin activation in vivo is known to be associated with inflammatory conditions, implicate thrombin as a major player in inflammation.

The deposition of fibrin is a common feature at the site of bacterial infection (13). Endotoxin can induce fibrin accumulation in vivo through the Shwartzman reaction (14), presumably by activating monocytes to express tissue factor (15). For this reason it is recognized as the component primarily responsible for blood coagulation associated with bacterial infections. Proteinases from such foreign sources are also thought to be virulence factors involved in various inflammatory events occurring at infected sites (16). For example, many of these enzymes present in snake venoms are known to activate prothrombin (17, 18); however, whereas bacterial proteinases may be able to convert prothrombin to thrombin, such a process has not been studied in detail.

A close relationship between Porphyromonas gingivalis (formerly Bacteroides gingivalis) and adult periodontitis has been reported (19-21), with proteolytic enzymes that are known to be produced in large quantity by this microorganism and have been shown to act as important pathogenic agents (22-24). From the culture medium of P. gingivalis HG66 we have purified previously two major forms of arginine-specific cysteine proteinases, HRgpA1 and RgpB, formerly referred to as high molecular mass gingipain R (95-kDa gingipain R1 or HRGP) and 50-kDa gingipain R2 (RGP-2), respectively (24, 26). Both of these enzymes are products of two distinct but related genes (27). rgpA encodes a polyprotein which, after post-translational processing/modifications, yields three different forms of the enzyme (28, 29); the major one is a non-covalent complex containing separate catalytic and adhesion/hemagglutinin domains (HRgpA). In contrast, the fragment encoding the latter domain(s) is missing in the rgpB gene structure, and its translation product is a single protein with a primary structure essentially identical to the catalytic domain of HRgpA (30, 31). Despite both a structural similarity and a specificity restricted to Arg-Xaa peptide bonds, HRgpA and RgpB show considerable differences in catalytic potency (26) which is most profoundly manifested in their ability to activate factor X (32) and protein C (33). In addition to activation of these members of the coagulation cascade pathway, it was also shown that RgpB was capable of generating kallikrein from plasma prekallikrein (16). Thus, it may be anticipated that gingipains R could activate other coagulation cascade proenzymes in this pathway, since each of these processes requires cleavage of peptide bonds at the carboxyl-terminal side of specific arginine residues (34). In the present study, we describe the results of experiments designed to investigate the ability of two forms of gingipains R to convert prothrombin to thrombin, an enzyme known to have multiple functions in both coagulation and pro-inflammatory processes.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Benzoyl-L-arginine-p-nitroanilide, tosyl-L-lysine chloromethyl-ketone (TLCK), leupeptin, and fibrinogen were purchased from Sigma. Factor X-deficient plasma was obtained from George King Bio-Medical, Inc. (Overland Park, KS). Purified human prothrombin, alpha -, beta -, and gamma -thrombins, and biotinylated Phe-Pro-Arg-chloromethyl ketone were purchased from Hematologie Technologies, Inc. (Essex Junction, VT). t-Butyloxycarbonyl-L-Val-L-Pro-L-Arg-4-methylcoumaryl-7-amide (Boc-Val-Pro-Arg-MCA) was obtained from the Peptide Institute (Minoh, Japan); p-nitrophenyl-p'-guanidinobenzoate was a product from Nacalai Tesque (Kyoto, Japan), and DX-9065a, a specific factor Xa inhibitor, was obtained from Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan). The purified human factor X was purchased from Enzyme Research Laboratories, Inc. (South Bend, IN). Factor X-, IX-, and XI-deficient plasmas and Platelin® (rabbit brain phospholipids) were obtained from George King Biomedical (Overland Park, KS), and from Organon Teknika (Durham, NC), respectively. Normal human plasma was prepared by centrifugation of a mixture of 9 volumes of freshly drawn blood from healthy volunteers and 1 volume of 3.8% (w/v) sodium citrate.

Proteinase Purification-- RgpB and HRgpA were isolated according to the method described by Potempa et al. (26). The amount of active enzyme in each purified proteinase was determined by active site titration using Phe-Pro-Arg-chloromethyl ketone (35), with the concentration of active gingipain R being calculated from the amount of inhibitor needed for complete inactivation of the proteinase.

Activation of Proteinases-- Each P. gingivalis proteinase was activated with 10 mM cysteine in 0.2 M HEPES buffer, pH 8.0, containing 5 mM CaCl2 at 37 °C for 10 min. The activated proteinase (2 µM) was diluted with 10 mM Tris-HCl, pH 7.3, containing 150 mM NaCl (TBS) and 5 mM CaCl2 prior to use.

Determination of Prothrombin Concentration-- The molar concentration of purified prothrombin was calculated using A<UP><SUB>280 nm</SUB><SUP>1%</SUP></UP> = 13.8 and a molecular mass of 72 kDa (36).

Clotting Assay-- The fibrinogen clotting activity of released thrombin was measured by incubating 90 µl of prothrombin (90 µg/ml) with 10 µl of a given proteinase at 37 °C for 3 min. One hundred µl of fibrinogen (3 mg/ml), prewarmed to 37 °C, was then added to the mixture, and the clotting time was measured with a Coagulometer KC 1A (Amelung, Lemgo, Germany). For plasma clotting time assays, 90 µl of factor X-deficient plasma supplemented with 4 µM factor X-specific inhibitor (DX-9065a) or the same plasma reconstituted with 10 µl of factor X (100 µg/ml) in the absence of DX-9065a were prewarmed to 37 °C, and then 10 µl of a proteinase was added and the clotting time measured. For activated partial thromboplastin time (APTT) assay, 90 µl of citrated plasma was mixed with 90 µl of PTT-LT® (cephalin 1.2 mg/ml, silica 1 mg/ml) (Roche Molecular Biochemicals) and preheated to 37 °C in a plastic cell for 1 min. Then, 20 µl of HRgpA was added, and the mixture was incubated at 37 °C for 2 min. After adding 100 µl of 25 mM CaCl2, the clotting time was measured with a Coagulometer KC 1A (Amelung, Lemgo, Germany).

Kinetic Analysis of Prothrombin Activation-- Prothrombin, dissolved in 50 µl of 0.1 M Tris-HCl, pH 7.6, containing 0.15 M NaCl and 5 mM CaCl2, was incubated with the same volume of either gingipain R (0.1 nM HRgpA or 0.4 nM RgpB final concentration) dissolved in the same buffer supplemented with 80 µg/ml phospholipids at 37 °C for 30, 60, 90, or 120 s. Then, 50 µl of 6 µM leupeptin in the same buffer was added, to inhibit completely the cysteine proteinase activity. At this concentration leupeptin does not affect the amidolytic activity of thrombin. To this mixture 50 µl of a thrombin-specific substrate, Boc-Val-Pro-Arg-MCA (0.4 mM), in the same buffer was added. Substrate cleavage and the release of AMC by thrombin was monitored by the relative fluorescence increase at 440 ± 20 nm after excitation at 380 ± 20 nm, using a microplate fluorescence spectrophotometer (CytoFluor Series 4000, Perspective Biosystems). To calculate concentrations of thrombin produced by either gingipain R, the amidolytic activity of purified alpha -thrombin, which had been titrated with p-nitrophenyl-p'-guanidinobenzoate (37), was used as a standard. The initial velocity of thrombin production at various prothrombin concentrations (final concentrations: 50, 100, 150, 200, 300, 400, 600, and 1000 nM for HRgpA and 1, 2, 3, 4, 5, 7, and 10 µM for RgpB) was determined by the best fit line after incubation for various periods. The values for Km and Vmax were extracted by direct fit of the Michaelis-Menten equation to experimental data using non-linear curve fitting employing the method of least squares with Taylor expansion (38). Moreover, because the values generated in this way were very similar to the ones obtained by three transformations of the Michaelis-Menten equation ([S]0/v versus [S]0, 1/v versus 1/[S]0 and v versus v/[S]0, where v and [S]0 denote the catalytic rate and the initial substrate concentration, respectively), the means ± S.D. derived from four independent experiments and four different transformations of the Michaelis-Menten equation were calculated and presented in Table IV.

SDS-Polyacrylamide Gel Electrophoresis and Western Blot Analysis-- Eighteen microliters of activated HRgpA or RgpB (3.6 pmol) were added to 162 µl of prothrombin (3.68 nmol in 0.1 M Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM CaCl2, and 0.5 mM benzamidine), and the mixture (20 nM and 20 µM final concentration of HRgpA or RgpB and prothrombin, respectively) was incubated at 37 °C. At 0.5 mM concentration, benzamidine inhibits thrombin activity but not that of gingipains, and it was included into the assay buffer to avoid autocatalytic cleavage. At specific time intervals, aliquots were withdrawn, and 1.5 µl of D-Phe-Phe-Arg-chloromethyl ketone (10 mM) was added to terminate the reaction. Samples were boiled in reducing treatment buffer and applied for SDS-PAGE with 10% slab gels, according to the method of Laemmli (39).

For Western blot analysis 2-µl aliquots of the prothrombin/gingipain incubation mixture were transferred to 8 µl of HEPES, pH 7.6, containing 10 µM biotinylated Phe-Pro-Arg-chloromethyl ketone, incubated for 10 min at room temperature, and boiled in reducing treatment buffer. After SDS-PAGE the separated protein fragments were electroblotted onto a polyvinylidene difluoride membrane (Hybond-P membrane from Amersham Pharmacia Biotech). The membrane was incubated with streptavidin-horseradish peroxidase conjugate, and bands were developed by enhanced chemiluminescence (Amersham Pharmacia Biotech).

Amino-terminal Sequence Analysis-- Automatic sequence analysis was performed with a pulse liquid-phase sequencer (model 477A Protein Sequencer, PerkinElmer Life Sciences/Applied Biosystems Inc.). To determine the amino-terminal sequence of prothrombin-derived fragments, the mixture was separated by SDS-PAGE and transferred to ImmobilonTM polyvinylidene difluoride transfer membrane (Millipore Co., Ltd., Bedford, MA). The transferred proteins were visualized by staining with Coomassie Brilliant Blue R-250. Excised bands were placed on a Polybrene-treated glass filter prior to sequence analysis.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Activation of Human Prothrombin by Gingipains R-- In order to determine whether gingipains R activate prothrombin, each bacterial proteinase was incubated with the human zymogen, and the release of thrombin activity was measured. Both proteinases caused prothrombin activation in a dose- and incubation time-dependent manner (Fig. 1, A and B), with HRgpA being nearly 17 times more potent. At conditions used for SDS-PAGE analysis of the prothrombin degradation pattern (Fig. 3), the thrombin activity released from 20 µM prothrombin by 20 nM of either gingipain transiently reached a peak after 10 min of incubation and then slowly disappeared during prolonged enzyme exposure (Fig. 2). Significantly, no generation of thrombin activity was observed if prothrombin was incubated with TLCK-treated gingipains R (Fig. 1).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Activation of human prothrombin by HRgpA and RgpB. Ninety µl of human prothrombin (90 µg/ml dissolved in 0.1 M Tris-HCl, pH 7.6, 150 mM NaCl, and 2.5 mM CaCl2) was supplemented with 10 µl of a proteinase and incubated at 37 °C (final prothrombin concentration, 1.12 µM). Activation was quenched with 500 µl of the above buffer containing 1.5 µM antipain. Ten microliters of Boc-Val-Pro-Arg-MCA (10 mM) was then added to the solution, and 7-amido-4-methylcoumarin released was measured at 37 °C. A, proteinases of various concentrations incubated with prothrombin for 3 min. The final concentrations of each proteinase in the reaction mixture are shown. open circle , HRgpA; triangle , RgpB; black-square, a mixture of TLCK-inactivated HRgpA and RgpA. B, proteinase (0.05 nM, final concentration) was incubated with prothrombin at 37 °C for various periods. open circle , HRgpA; triangle , RgpB; , TBS instead of a proteinase solution.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Time course of thrombin generation and degradation by gingipains R. Eighteen microliters of activated HRgpA (3.6 pmol) was added to 162 µl of prothrombin (3.68 nmol), and the mixture (20 nM and 20 µM final concentration of HRgpA and prothrombin, respectively) was incubated at 37 °C in 0.1 M Tris-HCl, 150 mM NaCl, 5 mM CaCl2, pH 7.6, containing 1 mM cysteine. At the given time intervals 10-µl aliquots were removed to 985 µl of the same buffer supplemented with 2 mM antipain, and thrombin activity released by HRgpA (open circle ) and RgpB (triangle ) was measured using H-D-Phe-Pipecolyl-Arg-p-nitroanilide as substrate.

Due to autoproteolytic cleavage or fragmentation by other proteolytic enzymes, thrombin in vitro can occur in three major forms referred to as alpha -, beta -, and gamma -thrombin. All of these enzymes have amidolytic activity, but only alpha -thrombin is capable of clotting fibrinogen. Therefore, to determine if amidolytic activity released by gingipains from the zymogen is at least partially due to the presence of alpha -thrombin, which is the more important form of this proteinase, the samples of prothrombin incubated with gingipains were examined for clotting activity. As summarized in Table I both gingipains induced fibrinogen clotting activity from prothrombin in a time- and concentration-dependent manner. However, due to the apparent progressive cleavage of the alpha -thrombin B-chain and the creation of beta - and/or gamma -thrombin, a correlation between clotting and amidolytic activity was observed only at short preincubation times. Indeed, after prolonged incubation the former activity decreased much faster than the latter activity (data not shown). The same process of excessive alpha -thrombin cleavage in the presence of increased concentrations of gingipains most likely skewed a concentration-dependent release of fibrinogen clotting activity from prothrombin. This is particularly apparent in the case of RgpB where the doubling of enzyme concentration resulted only in the moderate shortening of the fibrinogen clotting time (Table I). In comparison to HRgpA, an ~5-fold higher concentration of RgpB was necessary to induce clotting activity from prothrombin, and significantly, clotting times determined after the same preincubation time were 3-4 times longer. Taken together, these results indicate that HRgpA is about 20 times more efficient than RgpB in alpha -thrombin generation. This is in keeping with zymogen activation as measured with an amidolytic substrate in which HRgpA was shown to be 17-fold more efficient than RgpB (Fig. 1).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Fibrinogen clotting by prothrombin incubated with gingipains R
Ninety µl of prothrombin (90 µg/ml) was preincubated at 37 °C for 3 min before it was supplemented with 10 µl of a proteinase. One hundred µl of fibrinogen (3 mg/ml) prewarmed at 37 °C was then added to the mixture, and the clotting time was measured. Each value denotes the mean ± S.D. in triplicate assays.

The prothrombin activation assays in vitro based on generation of amidolytic and/or fibrinogen clotting activities do not reflect the complexity of reactions in blood plasma where a multitude of other proteins could hinder the interaction of gingipains R with prothrombin. Therefore, to determine if gingipains R can produce a significant amount of alpha -thrombin in plasma, we measured the clotting time of factor X-deficient plasma incubated with gingipains. In order to evaluate interference from any residual factor X, which may still exist in deficient plasma, the assay was performed in the presence of a factor Xa-specific inhibitor in comparison to the deficient plasma reconstituted with the physiological concentration of factor X. The results obtained are summarized in Table II and show that only HRgpA was able to clot factor X-deficient plasma in a dose-dependent manner, clearly indicating the generation of alpha -thrombin. The clotting time of the plasma reconstituted with factor X and incubated with HRgpA was basically the same, apparently due to the fact that in the absence of phospholipids and Ca2+ factor Xa is a very poor activator of prothrombin. This result indicates that the presence of factor X does not affect prothrombin activation by HRgpA. Significantly, in this assay HRgpA was shown to be at least 10-fold more efficient than RgpB. These results correlate very well with the ability of both gingipains R to induce fibrinogen clotting by prothrombin (Table I) and confirm that out of two gingipains R, HRgpA is the predominant activator of this zymogen.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of gingipains R on factor X-deficient plasma clotting time
Ninety µl of factor X-deficient (FX-def.) plasma in a plastic cell was supplemented with 10 µl of factor X-specific inhibitor (DX-9065a) or reconstituted (rec.) with the purified factor X (100 µg/ml), both in TBS. Samples were prewarmed to 37 °C, and then 10 µl of proteinase was added and the clotting time measured. Each value denotes the mean ± S.D. in triplicate assays.

In addition to the ability to generate directly alpha -thrombin from prothrombin, gingipains R are capable of efficiently activating factors X and IX and accelerating in this way plasma coagulation through the cascade reaction of the clotting factors in the presence of phospholipids and Ca2+ (32, 40). In order to understand the relative importance of these three activities, we have directly compared the ability of HRgpA to promote the clotting of normal plasma versus factor X-, IX-, and XI-deficient plasmas by measuring APTT. This assay using phospholipids, and Ca2+ enables us to study the plasma clotting via the cascade reaction. From the data summarized in Table III, it is also apparent that in this assay HRgpA, in concentrations much lower than those required in the plasma clotting assay, significantly decreased APTT in a dose-dependent manner not only in the normal plasma but also in plasmas deficient in factors X, IX, and XI. Although shortening of the clotting time of factor IX-deficient plasma is most likely due to the additive effect of activation of factor X and prothrombin, the clotting of factor X-deficient plasma must be predominantly triggered by generation of alpha -thrombin directly from the zymogen of this key clotting factor. Taken together these results further confirm that prothrombin is, indeed, an important pathological target for the HRgpA-mediated blood coagulation and indicate that this process can occur in vivo.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Effect of HRgpA on APTT of plasmas deficient in a factor in the intrinsic coagulation pathway
Ninety µl of citrated plasma was mixed with 90 µl of PTT-LT® (1.2 mg/ml cephalin, 1 mg/ml silica) and preheated to 37 °C in a plastic cell for 1 min. Then 20 µl of HRgpA was added, and the mixture was incubated at 37 °C for 2 min. After adding 100 µl of 25 mM CaCl2, the clotting time was measured. Each value denotes the mean ± S.D. in triplicate assays.

Cleavage of Prothrombin by Gingipains R-- To elucidate further the mechanism of prothrombin activation, the zymogen was incubated with gingipains R for various times, and the products obtained were analyzed by SDS-PAGE. The major polypeptide bands were then subjected to amino-terminal amino acid sequence analysis. From both the electrophoretic mobility and amino-terminal sequence of each prothrombin-derived fragment, bands of apparent molecular mass of 55, 45, 38.5, 34, 33, 23, and 15 kDa were found and indicated as being prethrombin 1 (fragment 2/A-chain/B-chain), fragment 1·2, prethrombin 2 (A-chain/B-chain), B-chain of alpha -thrombin, fragment 1, B-2-chain of beta -thrombin, and fragment 2, respectively (Fig. 3A).


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 3.   Cleavage of prothrombin by gingipains R. A, prothrombin (20 µM) and gingipains R (20 nM) were incubated together as described in Fig. 2 legend in the buffer supplemented with 0.5 mM benzamidine. At specific time intervals, aliquots were withdrawn, and 1.5 µl of D-Phe-Phe-Arg-chloromethyl ketone (10 mM) was added to terminate the reaction. Samples were boiled in sample treatment buffer and analyzed by SDS-PAGE. Lane a, prothrombin alone (3.5 µl loaded); lanes b-f, prothrombin incubated with HRgpA for 1, 2, 5, 15, and 60 min, respectively; lanes g and n, alpha -thrombin (1.3 µg loaded); lanes h-m, prothrombin incubated with RgpB for 0, 1, 2, 5, 15, and 60 min, respectively; lanes o-r, alpha -thrombin (20 µM) incubated with RgpB (20 µM) for 0, 5, 15, and 60 min, respectively (2 µg loaded); lanes s and t, pure beta - and gamma -thrombin, respectively (1.3 µg loaded). The positions of molecular mass standard markers are indicated to the right of the gel. The major fragments of prothrombin indicated by arrows were subjected to amino-terminal sequence analysis and identified as follows: 1, prethrombin 1; 2, fragment 1·2; 3, prethrombin 2; 4, B-chain of alpha -thrombin; 5, fragment 1; 6, B-2-chain of beta -thrombin; and 7, fragment 2. B, schematic diagram of prothrombin fragmentation with major cleavage sites for HRgpA and RgpB. The size of arrowheads indicates the relative efficiency of cleavage of specific peptide bonds in the prothrombin polypeptide chain by the two proteinases tested. beta -Thrombin is generated by cleavage at the Arg70-Tyr71 or Arg73-Asn74 peptide bonds in the alpha -thrombin B-chain, giving rise to the B1 and B2 peptides. An additional cleavage at Lys154-Gly155 of the B2-chain generates gamma -thrombin.

Despite large differences in the efficiency of prothrombin activation by HRgpA and RgpB, the zymogen digestion pattern was similar as determined by laser densitometry analysis (data not shown) of the gels shown in Fig. 3A. With HRgpA digestion it is clear that the first major cleavages occurred specifically at the Arg271-Thr272 and/or Arg320-Ile321 peptide bonds, releasing simultaneously fragment 1·2, prethrombin 2, and alpha -thrombin, followed by hydrolysis of fragment 1·2 at the Arg155-Ser156 peptide bond (Fig. 3B). In contrast, during the initial phases of prothrombin degradation by RgpB two major cleavages were found to take place at the Arg155-Ser156 and Arg271-Thr272 peptide bonds, leading to the initial accumulation of prethrombin 1, prethrombin 2, fragment 1 (Fig. 3A, lanes i and j), and only a minor amount of alpha -thrombin. In this regard the non-effective cleavage of the Arg320-Ile321 peptide bond in prothrombin explains why RgpB is about 20-fold slower in alpha -thrombin generation than HRgpA. Taken together, differences in the pattern of prothrombin-derived products generated by HRgpA and RgpB can be observed only at the initial incubation times with qualitative difference limited to release of B-chain of alpha -thrombin only by HRgpA. The variations in the rate of cleavage of the Arg155-Ser156 peptide bond contributed only to qualitative difference that was later annihilated by further cleavage to the same molecular mass fragments or digestion to small molecular peptides poorly visible in the gels.

The initial accumulation of prethrombin 2 during 15 min of incubation (Fig. 3A, lanes b-d and i-k) indicates that the peptide bond (Arg320-Ile321) at the junction between the A- and B-chains in prethrombin 2 is relatively refractory to cleavage by gingipains. The lack of conversion of prethrombin 2 into alpha -thrombin, as shown by both SDS-PAGE (Fig. 3A, lanes e and l) and the time course for the generation of thrombin activity (Fig. 2), argues that this form of zymogen is only a minor intermediate source of active enzyme that undergoes exhaustive degradation by gingipains. Such an interpretation is supported by the appearance of peptide fragments of lower molecular mass than prethrombin 2 but bearing the same amino-terminal sequence (Fig. 3, lanes d and k, bands between B-2-chain and fragment 2).

Significantly, RgpB was able to convert alpha -thrombin to beta -thrombin by cleavage at the Arg383-Asn394 peptide bond, with release of both the B-1- and B-2-chains (Fig. 3A, lanes p-r). Furthermore, the B-2-chain was slowly degraded by this gingipain, resulting in a gradual loss of enzymatic activity. In the case of HRgpA interacting with alpha -thrombin a similar pattern was observed, but the substrate cleavage occurred at higher rate, and after 60 min all alpha -thrombin was totally degraded to lower molecular mass fragments with similar electrophoretic mobility as those generated by RgpB. One significant but only qualitative difference was the low amount of accumulated B-2-chain of beta -thrombin which apparently was further degraded by HRgpA (data not shown). There may be some more profound differences in the cleavage pattern of alpha -thrombin, but weak staining of low molecular peptides in the gel excludes the possibility to analyze this in detail.

The active site labeling of the active thrombin forms generated during prothrombin incubation with gingipains fully substantiates the conclusion drawn from the SDS-PAGE analysis that alpha -thrombin is, indeed, directly released from the zymogen (Fig. 4, A and B). Note that in Fig. 4 the blot with prothrombin-derived products generated by digestion with RgpB was exposed about 15 times longer (Fig. 4B) than the other blot (Fig. 4A), in order to visualize the biotinylated active forms of thrombin. This provides supplementary evidence that HRgpA is a far more potent prothrombinase than RgpB. In addition, labeling experiments confirmed that the alpha -thrombin initially accumulated is the subject of further degradation in order to yield products that still preserve activity as indicated by incorporation of the biotinylated chloromethyl ketone. During prolonged incubation with HRgpA, the accumulation of the labeled B-4-like chain derived from gamma -thrombin-like molecule was apparent. In contrast, RgpB generated relatively minor amounts of gamma -thrombin-like derived peptide. Rather, it resulted in the significant accumulation of a labeled low molecular mass peptide, suggesting the generation of a form of thrombin with the B-chain fragmented to smaller pieces than those in gamma -thrombin (Fig. 4A).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Western blot analysis of different forms of active-site biotinylated thrombin generated during prothrombin incubation with gingipains R. Prothrombin was incubated with HRgpA (A) or RgpB (B) as described in the legend for Fig. 2. At specific time intervals, 2-µl aliquots were transferred to 8 µl of 0.1 M HEPES, pH 7.6, containing 10 µM biotinylated Phe-Pro-Arg-chloromethyl ketone. After 10 min of incubation at room temperature, samples were boiled in reducing treatment buffer and subjected to SDS-PAGE, followed by protein electrotransfer onto polyvinylidene difluoride membranes. The blotted membranes were incubated with streptavidin-horseradish peroxidase conjugate, and bands were developed by enhanced chemiluminescence for about 6 and 90 s for HRgpA and RgpB digestion products, respectively. Lanes a-g, prothrombin preincubated with each gingipain for 0, 0.5, 1, 2, 5, 15, and 60 min, respectively; lane h, a mixture of alpha -, beta -, and gamma -thrombin; lane i, prothrombin preincubated with TLCK-treated gingipain for 60 min.

Effect of Phospholipids and Ca2+ on Prothrombin Activation by Gingipains R-- Phospholipids and Ca2+ are important cofactors accelerating the proteolytic cascade reaction of coagulation factors. Therefore, we studied their effect on prothrombin activation by gingipains R. Thrombin production by HRgpA increased in phospholipid in a concentration-dependent manner, with the effect reaching a plateau at concentrations above 40 µg/ml. At this point phospholipids augmented prothrombin activation by HRgpA about 1.5-fold over the control. Interestingly, phospholipids did not affect prothrombin activation by RgpB. Phospholipids also did not increase prothrombin activation by HRgpA in the absence of Ca2+, and the prothrombin activation by the two proteinases was not affected by Ca2+ in the absence of phospholipids (data not shown).

Kinetics of Prothrombin Activation by Gingipains R-- To investigate the kinetics of prothrombin activation by gingipains R, the values of Km and kcat were measured in the presence of phospholipids (40 µg/ml) and determined as 0.26 ± 0.01 µM and 0.32 ± 0.02 s-1 for HRgpA and 6.6 ± 0.4 µM and 0.076 ± 0.005 s-1 for RgpB, the catalytic efficiency (kcat/Km) of the former enzyme was 100-fold higher than that of RgpB. The kinetic constants of gingipains R for prothrombin conversion to thrombin were compared with those for activated factor X (Xa) in the presence of activated factor V (Va) (41), as well as with snake venom prothrombin activators from Oxyuranus scutellatus (OSV-PTA) and Notechis scutulus scutulus (NSSV-PTA), again in the presence of factor Va (7, 8). The Km value of HRgpA was comparable to the values of the physiological prothrombin activator and venom prothrombin activators but much lower than the Km value of RgpB (Table IV). In addition, the kcat values of gingipains R were also less than that of factor Xa and OSV-PTA, although higher than the value of NSSV-PTA (Table IV). The kcat/Km values of the bacterial proteinases were substantially lower than those of factor Xa and OSV-PTA, but the value for HRgpA was higher than that of NSSV-PTA (Table IV). Significantly, the kcat/Km value of RgpB, which contains no adhesin domain, was the lowest of the five compared. These data suggest that HRgpA is a more potent prothrombin activator than RgpB and NSSV-PTA, although it is less potent than either factor Xa or OSV-PTA.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Kinetic constants for the activation of prothrombin
The mean ± S.D. of the Km and kcat values for prothrombin activation by gingipains were calculated from data obtained in four independent experiments. For details see under "Experimental Procedures."


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

With the exception of staphylocoagulase which causes human plasma coagulation through formation of an active molecular complex with prothrombin (42), surprisingly little is known as to how bacteria-derived proteins interact with this zymogen. Indeed, until now the only bacterial proteinase that had been shown to activate prothrombin by limited proteolysis was a metalloproteinase from Staphylococcus aureus (43). Our data indicate, however, that the activity of this proteinase was several thousand-fold lower than that of either of the gingipains R (data not shown). The present work, therefore, demonstrates that gingipains R of P. gingivalis are the most potent proteolytic human prothrombin activators of bacterial origin yet described.

Although the catalytic domains of both gingipains R are essentially identical (30), these proteinases activated prothrombin with distinctly different kinetics. Taking into account that during prothrombin incubation with either gingipain the first active product was alpha -thrombin-released by simultaneous cleavage of prothrombin at Arg271-Thr272 and Arg320-Ile321 peptide bonds (Fig. 3), it is apparent that the data describe the direct generation of the physiologically active form of thrombin. The difference in the rate of the Arg320-Ile321 peptide bond cleavage is most likely to be responsible for the 17-fold less efficient prothrombin activation by RgpB than HRgpA, because it directly contributes to the kcat value of prothrombin activation that is 5 times lower for the former gingipain R. On the other hand, the presence of the hemagglutinin/adhesion domain in the HRgpA molecule may be responsible for the increased affinity of HRgpA to prothrombin in comparison to RgpB.

In pathophysiological conditions in vivo where the substrate concentration is set, the affinity of Rgps for prothrombin (Km) may be a factor limiting the ability of gingipains R to activate efficiently this zymogen. The Km value of HRgpA (0.26 µM) for prothrombin is 4-fold lower than the normal plasma concentration of this protein (around 80 µg/ml, 1.1 µM) (34) and comparable to the Km value of the prothrombinase complex (Table IV), supporting the likelihood that this gingipain may activate prothrombin in vivo. In contrast, the high Km value of 6.6 µM for RgpB interaction with prothrombin does not favor activation of this coagulation factor. In addition, RgpB activates prothrombin about 20 times slower than HRgpA explaining together why only the later gingipain R can clot plasma. Significantly, however, in comparison to fibrinogen, plasma clotting occurred at much higher gingipain concentrations. This discrepancy is predominantly due to the fact that in fibrinogen clotting experiments designed to prove that alpha -thrombin was generated, prothrombin was first preincubated with gingipains R before being mixed with fibrinogen, whereas in the plasma clotting test there was no preincubation step. Second, interference from other plasma proteins in gingipain R prothrombin activation and/or by degradation of fibrinogen by gingipains R (44) could also add to slower plasma clotting. In contrast, the absence of calcium in the plasma clotting assay should have no contribution to the observed difference since it was shown that Ca2+ affects neither prothrombin activation by gingipains R nor conversion of fibrinogen to fibrin by alpha -thrombin (34).

The superior ability of HRgpA in comparison to RgpB to activate prothrombin directly is most likely related to the presence of the hemagglutinin/adhesion domain in the former proteinase. It is conceivable that this domain participates in the initial binding of prothrombin to HRgpA, enforcing the proper orientation of the zymogen for proteolytic attack at the Arg271-Thr272 and Arg320-Ile321 peptide bonds, which is required for alpha -thrombin production. Because the hemagglutinin/adhesion domain is involved in high affinity binding of fibronectin and fibrinogen to HRgpA (44), these proteins, which occur in plasma at relatively high concentrations, may compete with prothrombin for binding to this bacterial proteinase. It is tempting to hypothesize that when fibrinogen or fibronectin occupies the hemagglutinin/adhesion domain of HRgpA; this complex behaves more like RgpB in its ability to activate prothrombin.

The significant difference between prothrombin activation by prothrombinase complex or OSV-PTA and gingipains R is the lack of prethrombin 2 conversion by the bacterial proteinases, as is apparent from transient accumulation of this form of partially processed zymogen under in vitro conditions (Fig. 3A). In vivo, however, in the presence of phospholipids any released prethrombin 2 may become instantly processed to alpha -thrombin by activated factor X generated in plasma by gingipains R (32). This ability to activate factor X by HRgpA was also shown to be 10-fold more efficient than RgpB, primarily due to a 7-8-fold acceleration of the reaction by phospholipids in the presence of Ca2+ (32). Because in the absence of phospholipids the catalytic potency of HRgpA to activate factor X is only 3-fold higher than RgpB, as indicated by the kcat/Km ratio, it is apparent that the preferential activation of blood coagulation by HRgpA is mainly due to the stimulatory effect of phospholipids. Therefore, in the absence of this cofactor HRgpA activates both prothrombin and factor X with comparable efficiencies. In contrast, kinetic data indicate that irrespective of the presence of phospholipids, RgpB acts preferentially on factor X, as described previously (32). This phenomenon may be explained by the fact that alpha -thrombin generation from its zymogen requires a concerted cleavage at two specific peptide bonds (Arg271-Thr272 and Arg320-Ile321) in prothrombin, whereas that of factor Xa needs a single cleavage at the Arg52-Ile53 in the heavy chain of this zymogen (34).

Taken together, the data presented here indicate that at a P. gingivalis-infected periodontitis site gingipains R, present in significant amount in the gingival crevicular fluid (45), are able to release locally alpha -thrombin by direct cleavage of prothrombin in the reaction uncontrolled by host factors that normally keep in check prothrombin activation. This may have significant effect on periodontal tissues because thrombin, in addition to being a key enzyme in the coagulation pathway, is the molecule endowed with several physiological functions relevant to pathological changes seen at the periodontitis site. First, it enhances vascular permeability and possesses leukocyte chemotactic activity (9-11) and, therefore, may account for gingival crevicular fluid formation and leukocyte accumulation. Second, it induces the production of prostaglandins (46, 47) and interleukin-1 (12), and the elevated levels of these two factors in gingival crevicular fluid of adult periodontitis patients (48-50) may be connected to thrombin production by P. gingivalis proteinases. Third, thrombin stimulates bone resorption by osteoclasts through a prostaglandin-dependent pathway (46) and thus could be associated with the alveolar bone resorption seen at periodontitis sites. All together, the data described here would imply that the conversion of prothrombin to alpha -thrombin is a potentially important mechanism for the alveolar bone erosion, a practically irreversible clinical hallmark of periodontitis.

In addition to the potential role in the pathogenesis of periodontitis, our data provide a logical rationalization for the emerging relationship between periodontitis and cardiovascular disease (51, 52). First, gingipains would have an indirect role as factors aggravating and/or sustaining chronic inflammation. Second, they may contribute more directly to cardiovascular complications because P. gingivalis has been immunohistochemically in atherosclerotic plaque shoulders and macrophage-rich infiltrate has been associated with ulcer and thrombus formation (53). If these bacterial cells still express gingipains, it is conceivable that these proteinases could affect local homeostasis through effective and uncontrolled activation of both proteinase-activated receptors2 and coagulation factors.

    FOOTNOTES

|| Present address: IBMB-CSIC, Dept. de Biologia Molecular y Celular, Jordi Girona, 18-26, 08034 Barcelona, Spain.

Dagger Dagger To whom correspondence should be addressed: Institute of Molecular Biology, Jagiellonian University, Al. Mickiewicza 3, 31-120 Kraków, Poland. Tel.: 48-12-634-1442; Fax: 48-12-633-6907; E-mail: potempa@mol.uj.edu.pl.

Published, JBC Papers in Press, March 16, 2001, DOI 10.1074/jbc.M006760200

This work was supported by Grant 11670219 from the Japanese Ministry of Education (to T. I.), Grant DE 09761 from the National Institutes of Health (to J. T.), and by Grant 6 P04A 047 17 from the Committee of Scientific Research, KBN, Warszawa, Poland (to J. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

2 Lourbakos, A., Yuan, Y. P., Jenkins, A., Travis, J., Andrade-Gordon, P., Santulli, R., Potempa, J., and Pike, R. N. (2001) Blood, in press.

    ABBREVIATIONS

The abbreviations used are: HRgpA and RgpB, arginine-specific gingipains, products of rgpA and rgpB genes, respectively; PT, prothrombin time; TLCK, tosyl-L-lysine chloromethyl ketone; PAGE, polyacrylamide gel electrophoresis; APTT, activated partial thromboplastin time; Boc-Val-Pro-Arg-MCA, t-butyloxycarbonyl-L-Val-L-Pro-L-Arg-4-methylcoumaryl-7-amide.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Nemerson, Y. (1988) Blood 71, 1-8[Medline] [Order article via Infotrieve]
2. Drake, T. E., Morrissey, J. H., and Edgington, T. S. (1989) Am. J. Pathol. 134, 1087-1097[Abstract]
3. Colman, R. W., Marder, V. J., Salzman, E. W., and Hirsh, J. (1987) in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W. , Hirsh, J. , Marder, V. J. , and Salzman, E. W., eds), 2nd Ed. , pp. 3-17, J. B. Lippincott, Philadelphia, PA
4. Mann, K. G. R., and Lundblad, L. (1987) in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W. , Hirsh, J. , Marder, V. J. , and Salzman, E. W., eds), 2nd Ed. , pp. 148-161, J. B. Lippincott, Philadelphia, PA
5. Furie, B., and Furie, B. C. (1988) Cell 53, 505-518[Medline] [Order article via Infotrieve]
6. Coughlin, S. R. (1999) Thromb. Haemostasis 82, 363-356
7. Coughlin, S. R. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11023-11027[Abstract/Free Full Text]
8. Fenton, J. W., II (1986) Ann. N. Y. Acad. Sci. 485, 5-15[Medline] [Order article via Infotrieve]
9. DeMichele, M. A. A., Moon, D. G., Fenton, J. W., II, and Minnear, F. L. (1990) J. Appl. Physiol. 69, 1599-1606[Abstract/Free Full Text]
10. Bizios, R., Lai, L., Fenton, J. W., II, and Malik, A. B. (1986) J. Cell. Physiol. 128, 485-490[Medline] [Order article via Infotrieve]
11. Bar-Shavit, R., Kahn, A., Fenton, L. W., II, and Wilner, G. D. (1983) Science 220, 728-730[Medline] [Order article via Infotrieve]
12. Jones, A., and Geczy, C. L. (1990) Immunology 71, 236-241[Medline] [Order article via Infotrieve]
13. Menkin, V. (1938) Physiol. Rev. 18, 366-418[Free Full Text]
14. Lipinski, B., Nowak, A., and Gurewich, V. (1974) Br. J. Haematol. 28, 221-231[Medline] [Order article via Infotrieve]
15. Rivers, R. P., Hathaway, W. E., and Weston, W. L. (1975) Br. J. Haematol. 30, 311-316[Medline] [Order article via Infotrieve]
16. Imamura, T., Pike, R. N., Potempa, J., and Travis, J. (1994) J. Clin. Invest. 94, 361-367[Medline] [Order article via Infotrieve]
17. Speijer, H., Govers-Riemslag, J. W. P., Zwaal, R. F. A., and Rosing, J. (1986) J. Biol. Chem. 261, 13258-13267[Abstract/Free Full Text]
18. Tans, G., Govers-Riemslag, J. W. P., van Rijin, J. M. L., and Rosing, J. (1985) J. Biol. Chem. 260, 9366-9372[Abstract/Free Full Text]
19. Slots, J. (1982) in Host-Parasite Interactions in Periodontal Diseases (Genco, R. J. , and Mergenhagen, S. E., eds) , pp. 27-45, American Society of Microbiology, Washington. D. C.
20. Holt, S. C., Ebersole, J., Fenton, J., Brunsvold, M., and Kornmann, K. S. (1987) Science 239, 55-57
21. Zambon, J. J. (1990) in Contemporary Periodontics (Genco, R. J. , Goldman, H. M. , and Cohen, D. W., eds) , pp. 147-160, Mosby, St. Louis, MO
22. Grenier, D., and Mayrand, D. (1987) J. Clin. Microbiol. 25, 738-740[Medline] [Order article via Infotrieve]
23. Smalley, J. W., Birss, A. J., Kay, H. M., McKee, A. S., and Marsh, P. D. (1989) Oral Microbiol. Immunol. 4, 178-181[Medline] [Order article via Infotrieve]
24. Marsh, P. D., McKee, A. S., McDermid, A. S., and Dowsett, A. B. (1989) FEMS Microbiol. Lett. 59, 181-185
25. Pike, R., McGraw, W., Potempa, J., and Travis, J. (1994) J. Biol. Chem. 269, 406-411[Abstract/Free Full Text]
26. Potempa, J., Mikolajczyk-Pawlinska, J., Brassell, D., Nelson, D., Thogersen, I. B., Enghild, J. J., and Travis, J. (1998) J. Biol. Chem. 273, 21648-21657[Abstract/Free Full Text]
27. Nakayama, K., Kadowaki, T., Okamoto, K., and Yamamoto, K. (1995) J. Biol. Chem. 270, 23619-23626[Abstract/Free Full Text]
28. Pavloff, N., Potempa, J., Pike, R. N., Prochazka, V., Kiefer, M. C., Travis, J., and Barr, P. J. (1995) J. Biol. Chem. 270, 1007-1010[Abstract/Free Full Text]
29. Rangarajan, M., Aduse-Opoku, J., Slaney, J. M., Young, K. A., and Curtis, M. A. (1987) Mol. Microbiol. 23, 955-965
30. Mikolajczyk-Pawlinska, J., Kordula, T., Pavloff, N., Pemberton, P. A., Chen, W. C. A., Travis, J., and Potempa, J. (1998) Biol. Chem. 379, 205-211[Medline] [Order article via Infotrieve]
31. Nakayama, K. (1997) Microbiol. Immunol. 41, 185-196[Medline] [Order article via Infotrieve]
32. Imamura, T., Potempa, J., Tanase, S., and Travis, J. (1997) J. Biol. Chem. 272, 16062-16067[Abstract/Free Full Text]
33. Hosotaki, K., Imamura, T., Potempa, J., Travis, J., Hiraoka, T., and Kitamura, N. (1999) Biol. Chem. 380, 75-80[Medline] [Order article via Infotrieve]
34. Halkier, T. (1991) Mechanisms in Blood Coagulation, Fibrinolysis and the Complement System , Cambridge University Press, UK
35. Potempa, J., Pike, R., and Travis, J. (1997) Biol. Chem. 378, 223-230
36. Kisiel, W., and Hanahan, D. J. (1973) Biochim. Biophys. Acta 304, 103-113[Medline] [Order article via Infotrieve]
37. Chase, T., Jr., and Shaw, E. (1967) Biochem. Biophys. Res. Commun. 29, 508-514
38. Sakoda, M., and Hiromi, K. (1976) J. Biochem. (Tokyo) 80, 547-555[Abstract]
39. Laemmli, U. K. (1970) Nature 227, 680-684[Medline] [Order article via Infotrieve]
40. Imamura, T., Tanase, S., Hamamoto, T., Potempa, J., and Travis, J. (2001) Biochem. J. 353, 325-331[CrossRef][Medline] [Order article via Infotrieve]
41. Pusey, M. L., and Nelsestuen, G. L. (1983) Biochem. Biophys. Res. Commun. 114, 526-532[Medline] [Order article via Infotrieve]
42. Hemker, H. C., Bass, B. M., and Muller, A. D. (1975) Biochim. Biophys. Acta 379, 180-188[Medline] [Order article via Infotrieve]
43. Wegrzynowicz, Z., Heczko, P. B., Drapeau, G. R., Jeljaszewicz, J., and Pulverer, G. (1981) J. Clin. Microbiol. 12, 138-139
44. Pike, R. N., Potempa, J., McGraw, W., Coetzer, T. H. T., and Travis, J. (1996) J. Bacteriol. 178, 2876-2882[Abstract]
45. Wikström, M., Potempa, J., Polanowski, A., Travis, J., and Renvert, S. (1994) J. Periodontol. 65, 47-55[Medline] [Order article via Infotrieve]
46. Hoffmann, O., Klaushofer, K., Koller, K., Peterlik, M., Mavreas, T., and Stern, P. (1986) Prostaglandins 31, 601-608[Medline] [Order article via Infotrieve]
47. Lerner, U. H., and Gustafson, G. T. (1988) Biochim. Biophys. Acta 964, 309-318[Medline] [Order article via Infotrieve]
48. Offenbacher, S., Odle, B. M., and Van Dyke, T. E. (1986) J. Periodontolal. Res. 21, 101-112[Medline] [Order article via Infotrieve]
49. Tubb, M., Williams, F. E., and Fraizier, L. W. (1990) Arch. Oral Biol. 35, 529-533[Medline] [Order article via Infotrieve]
50. Masada, M. P., Persson, R., Kenney, J. S., Lee, S. W., Page, R. C., and Allison, A. C. (1990) J. Periodontolal. Res. 25, 156-163[Medline] [Order article via Infotrieve]
51. Beck, J., Garcia, R., Heiss, G., Vokonas, P. S., and Offenbacher, S. (1996) J. Periodontol. 67, 1123-1137[Medline] [Order article via Infotrieve]
52. Page, R. C. (1998) Ann. Periodontol. 3, 108-120[Medline] [Order article via Infotrieve]
53. Chiu, B. (2000) Am. Heart J. 138, 534-536


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.